Actuate Therapeutics CEO Daniel Schmitt purchases $49,999 in stock
What it means
- What to watch: There is a hard number in this story ($49,999) — the interesting part is how it compares with the last few like it.
- How the stock is trading: $ACTU -9.68% in the latest session.
- Timing: Weekend news: the change beside it is Friday's, and Monday's open is the first session that gets a say. Market holidays are not detected.
Where the stock stands
$ACTU last changed hands at $0.34, -9.68% on the session, 96% below its 52-week high of $7.90 and 1.5% above its low of $0.33 — within a tenth of its 52-week low. Over the year it has ranged 2294% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $ACTU page.
How much coverage it is getting
This is the only story Wook has logged on $ACTU in the last 30 days — a quiet name that just got a headline. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$ACTU earnings in 11 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
The $ACTU page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $ACTU is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ACTU. It carried $49,999, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.